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A Ab bs st tr ra ac ct t    Objective. The aim of this study is to verify whether consolidation 
chemotherapy with Cisplatin improves disease-free survival and/or overall 
survival in patients affected by epithelial ovarian cancer. 
Methods. A multicenter study examined 122 randomized patients in complete 
remission as judged by laparoscopy or laparotomy following first-line 
chemotherapy consisting of ACy (Adriamycin + Cyclophosphamide), PCy 
(Cisplatin + Cyclophosphamide), or Mitoxantrone + Carboplatin. Sixty-one of 
these patients were treated with 3 cycles of 5-Fluorouracil (FU) 500 mg/m2 
for 5 days followed by Cisplatin at 100 mg/m2 on the 6th or 7th day every 28 
days; the other 61 received no further treatment (nihil group). 
Results. Sixty patients in the Cisplatin arm were evaluable. There were 36 
relapses in the FU+Cisplatin arm and 30 in the nihil arm. Peritoneal relapses 
were 25% for Cisplatin treatment vs. 16.4 % for nihil. There were 29 deaths in 
the Cisplatin arm vs. 27 for nihil. Median overall survival time (95 months 
with Cisplatin vs. 96 months in the nihil group) and median disease-free 
survival (66 months with Cisplatin vs. 73 in the nihil group) were similar in 
both arms (p=0.66 and p=0.41, respectively). There were no significant 
differences in tumor stage and grade between the two arms. Seven patients 
presented a second neoplasm during follow-up: six in the nihil arm, but only 
one patient in the Cisplatin arm. Death in these patients was due to the 
second neoplasm and not to progression of ovarian cancer. 
Conclusion. Three courses of additional platinum+FU treatment after five 
cycles of first-line chemotherapy without FU produced no increase in overall 
survival or disease-free survival. 
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1.  Introduction 
Cure rates for advanced ovarian cancer are low, regardless of the type of treatment received. An 
average 5-year survival rate of 10% (0-15%) has been obtained with abdominal radiation therapy [1-4], 
and response rates vary from 3 to 30% with chemotherapy [5-9]. Recent multivariate analyses of 
prognostic factors suggest that the size of the residual tumor after first surgery is the most important 
variable in predicting the response to therapy [3]; for each 10% increase in maximum cytoreduction, 
survival increased by 5.5%. There was an average difference in survival of approximately 11 months 
between the less-than-25% and the greater-than-75% maximum cytoreduction cohorts [10]. 
The use of Cisplatin, which presents encouraging response rates, is associated with longer survival 
[11]; however, often the efficacy of highly aggressive regimens is only seen in those patients with 
highly favorable prognostic factors (optimal cytoreductive surgery). According to the Goldie-Coldman 
theory, early administration of aggressive regimens could selectively interfere with the number of drug-
resistant cells arising by spontaneous mutation, reducing them to a minimum [1] and therefore possibly 
neutralizing the risk of relapse. The relapse rate for epithelial ovarian carcinoma in pathologic Complete 
Remission is generally between 42 and 44% [12-14]. Abdominal radiotherapy as consolidation 
treatment produced forms of gastrointestinal toxicity, such as subocclusion and enteritis, without 
significant therapeutic advantage [15-17]. 
In early ovarian cancer, adjuvant chemotherapy is effective [18]; Trimbos et. al. reported results 
from a randomized trial, one conducted by the EORTC (European Organisation for Research and 
Treatment of Cancer) (ACTION Study) where immediate chemotherapy significantly improved 
recurrence-free survival with an absolute difference at five years of 8%, but with a greater advantage 
found among patients having had non-optimal staging or surgical treatment at inexperienced centers. 
However, other randomized studies have shown that disease-free survival and overall survival in 
advanced ovarian cancer do not vary in relation to the number of cycles of chemotherapy given, (6 vs. 9 
cycles of PAC [Platinum-Adriamycin-Cyclophosphamide] [19], 5 vs. 10 cycles of polychemotherapy 
with Cisplatin [20], 6 vs. 12 cycles of PAC [21] or 5 vs. 8 courses of platinum [22]), while still other 
trials on a small number of patients with absent disease or residuum <2cm (table 1) would seem to 
confirm the usefulness of radiotherapy or of chemoradiotherapy as consolidation [23]. 
2.  Patients and Methods 
From October 1988 to October 1996, 122 patients affected by epithelial ovarian cancer who had 
been found to be in complete remission, as judged by laparoscopy and/or laparotomy, entered the 
GOCCNE study (Gruppo Oncologico Cooperativo Clinico del Nord-Est, consisting of 20 centers in 
North-east Italy) designed to evaluate the usefulness of consolidation chemotherapy in patients with 
pathologic complete remission. First-line chemotherapy consisted of Anthracyclin-Cyclophosphamide 
for 54 patients, Mitoxantrone-Carboplatin for 5 elderly patients and Cyclophosphamide-Platinum for 63 
patients. Pathologic complete remission was assessed by CT scan in all patients; if this was negative, 
the same patients underwent laparoscopic control. All patients with negative laparotomy (70 pts; 
however, 1 pt. after a negative laparoscopy, at time of randomization resulted positive at second look 
laparotomy performed autonomously) and/or negative laparoscopic second looks (52 pts) were 
proposed for the study and randomly assigned to consolidation chemotherapy with 5-Fluorouracil + 
Cisplatin or nihil. 
Inclusion in the study was based on a histologically documented diagnosis, completion of first-line 
chemotherapy and a performance status higher than 60. In addition, it was required that patients have 
normal renal function (creatinine <2 mg/dL, BUN <45 mmol/L), hepatic function (conjugated bilirubin 
<2 mg/dL, ALP <150 U/L and γGT <80 U/L) and cardiac function (as judged by physical examination, 
measurement of pulse and arterial pressure and ECG). Patients were also required to give their informed 
consent. 
Patients over 80 years of age were excluded, as were patients with WBC counts <4000/mm
3 or 
platelets <140,000/mm
3. Patients presenting with second tumors, psychiatric disorders, brain metastases 
and those with altered ECGs, suggesting important conduction disturbances (dromotropic or 
bathmotropic), were also excluded. 
Consolidation chemotherapy with 5-Fluorouracil (5-FU) and Cisplatin consisted of 5-FU 500 
mg/m
2/day intravenously for 5 days, followed by Cisplatin at a dose of 100 mg/m
2 on the 6
th or 7
th day Int. J. Med. Sci. 2004 1(2): 116-125  118 
(never exceeding a total dose of 160 mg) associated with Allopurinol 300 mg/day. This was repeated 
every 28 days for 3 cycles. The choice of 5-Fluorouracil was based on the fact that 5-FU had been 
shown to be highly effective in salvage therapy for refractory ovarian cancer patients with low bulk 
disease [24, 25]. 
In cases developing arterial hypertension or myocardiosclerosis (with diastolic pressure 
>120mmHg) during treatment, the dose of 5-FU was reduced by 25%. The first day of 5-FU was 
abolished in cases of myelotoxicity protracted from the previous cycle (more than 5 weeks to recovery). 
Cisplatin was reduced by 50% in mononephric patients, or when obstructive nephropathy was 
encountered, as well as in cases of important hypacusia or neurotoxicity or in patients over 76 years of 
age. 
Statistical comparison of overall and disease-free survival was based on Kaplan-Meier estimates of 
survival and a log-rank test of statistical significance. 
3.  Results 
The study population consisted of 122 patients. Median age of both the consolidation therapy 
population and the nihil arm was 55 (range: 38-76 and 16-73, respectively). The stage distribution was 
15 pts stage I C, 30 pts stage II B and II C, 71 pts stage III, and 5 pts stage IV; histologic grade was 
grade 1 in 19 cases, 2 in 45 cases and 3 in 57 cases. Distribution of histological grade for the Cisplatin 
arm vs. the nihil arm was grade 1-2 in 30 vs. 34 cases and grade 3 in 30 vs. 27 cases. Characteristics of 
the two groups can be found in table 2. 
The 61 patients in the nihil arm completed 5 cycles of first-line chemotherapy only, while an 
additional 3 cycles of polychemotherapy with FU followed by Cisplatin were proposed for the 61 
patients in the Cisplatin arm. Of the 61 patients assigned to the Cisplatin arm, 47 (77.0%) completed 3 
or more cycles. However, 4 patients (6.6%) completed only 1 cycle while 9 patients (14.8%) completed 
2 cycles before suspending treatment (for noncompliance or for excessive gastrointestinal and/or 
neurological toxicity). One patient (1.6%) refused treatment entirely after randomization and is 
therefore not evaluable. Three of the 47 patients who completed 3 cycles continued treatment even 
further, receiving an additional 1-3 cycles of Cisplatin for a total of 4-6 cycles (table 2). 
The toxicity in treatment with Cisplatin consisted of nausea and vomiting in 38 patients (62.3% of 
Cisplatin-treated patients); this was WHO grade 3 in 17 pts (27.9%) and grade 4 in 10 pts (16.4%); it 
was neurological in 21 pts (34.4%), and consisted of leukopenia in 13 pts (21.3%), mucositis in 7 pts 
(11.5%), nephrotoxicity in 4 pts (6.6%), infection in 3 (4.9%) and anemia in another 2 (3.3%) pts (table 
3). 
The overall survival of the two groups was very similar (fig.1.). There were 36 relapses (59.0%) in 
the Cisplatin arm and 30 (49.2%) in the “nihil” arm. Peritoneal relapses varied for the two arms and 
were 15 (25%) for Cisplatin vs. 10 (16.4%) for nihil. Relapses in the vaginal dome were found in 1 case 
(1.7%) treated with Cisplatin and 5 (8.2%) in the nihil arm, while hepatic and splenic relapses were 
nearly identical. Relapses in lung-pleura were also similar: 5 (8.3%) in the Cisplatin arm vs. 6 (9.8%) in 
the nihil arm. Relapses in lumboaortic-inguinal lymph nodes were 11 (18.0%) in the Cisplatin arm and 
4 (6.6%) in the nihil arm (table 4). 
Seven patients presented a second neoplasm after treatment for ovarian cancer. There were two 
cases of breast cancer, two cases of sigmoid adenocarcinoma, one case of small cell lung cancer, one 
case of hypernephroma, and one case of head and neck cancer. Six of these patients were in the nihil 
arm. Only one patient (head and neck cancer) was in the Cisplatin arm. Death in these patients resulted 
from the second neoplasm and not from progression of ovarian cancer. 
Median overall survival was 87 months for the cisplatin arm (82.0% at 3 years) and 89 months for 
the nihil arm (80.3% at 3 years) (p=0.66, log rank test). Median disease free survival was 68 months 
(range 1.4-170.0) for the Cisplatin arm (62.1% at three years for the cisplatin arm) and 73 months 
(range 1.6-169.5) for the nihil arm (62.3% at three years for the nihil arm). There was no statistical 
difference between the two groups (p=0.41, log rank test). 
4.  Discussion 
Ovarian cancer patients have high response rates to initial chemotherapy after cytoreductive 
surgery. There are fewer complete responses with the use of anthracyclin and alkylating agents as first-
line treatment, although their duration is greater than the complete responses obtained by platinum Int. J. Med. Sci. 2004 1(2): 116-125  119 
chemotherapy [5]. Relapses occur in 30% of the cases within the first 3 years [26]. It is thus possible 
that the use of alkylating agents and anthracyclins could select responders who have a different 
prognosis from patients treated with a platinum-based regime. Unlike Gershenson [27] who sustains the 
usefulness of prolonged chemotherapy with platinum, other investigators have found that prolonging 
chemotherapy does not have any benefit in terms of survival [19-22]. 
In the literature there is no agreement regarding treatment of patients with ovarian cancer who are 
in complete remission following first-line chemotherapy, and no therapeutic modality shows a clear and 
definite advantage in terms of disease-free survival. Moreover, there are no large comparative 
randomized studies on this topic [19-21, 26]. 
In 1988 when the present trial was proposed there was uncertainty as to whether 3 additional 
courses of platinum based chemotherapy were useful in patients who had obtained complete remission 
after 5 courses of first-line chemotherapy with or without Cisplatin. The choice of Cisplatin + 5-FU was 
based on the fact that other drugs such liposomal Doxorubicin, Paclitaxel, or Topotecan were not 
available at that time. 
Radiation therapy was not chosen for consolidation treatment because the literature provided no 
studies to support a significant advantage over chemotherapy [26, 28, 29] while presenting local 
toxicity. Still, Pickle et al. [23], in a randomized study, demonstrated the usefulness of radiation therapy 
in association with chemotherapy in patients (predominantly stage III) who were judged free of disease, 
after radical surgery and six cycles of first-line chemotherapy, with respect to thirty-two patients who 
received only whole abdominal radiation following surgery. The overall and relapse-free survival was 
better for the group receiving combination chemo-radiotherapy, confirming the fundamental role of 
systemic treatment. 
Our experience with only 121 evaluable patients, however, suggests that there is no difference 
between chemotherapeutic consolidation after remission vs. nihil. This trial therefore seems to confirm 
the findings of other authors, namely that the 5-year-survival of patients without residual tumor mass 
following first surgery varies between 50 and 70% [3, 30], and that their survival is better than that of 
patients with residual mass <2 cm (which varies between 35-55%) or patients with residuum of 2 cm or 
more (which varies between 0-30%) [3, 7]. 
While statistical analysis of the present study does not note any significant difference in overall 
survival (fig. 1) or in disease-free survival (fig. 2) between the two arms suggesting that 
polychemotherapy with cisplatin is not very effective in a consolidative setting, it is limited by the lack 
of stratification by stage, and by previous type of chemotherapy (table 2) as well as by the limited 
number of patients randomized (122 pts). The lack of stratification might have resulted in the selection 
of a population with better prognostic factors in the nihil arm vs. the Cisplatin arm, thereby creating a 
bias; thus, this result should be evaluated with caution 
It is worth noting that many of our patients had not been previously treated with platinum, and yet 
survival rates were similar to those for patients with platinum based first-line therapy. This would seem 
to cast doubts on the long-term efficacy of platinum therapy in ovarian cancer. 
In our study severe toxicity was rare with the exception of grade 3-4 emesis encountered in 44,3%. 
Severe nausea was controlled in most of the patients; however, in 21.3% of patients toxicity was severe 
enough to suspend treatment either for non-compliance or for excessive gastrointestinal toxicity, thus 
cycles were suspended in 13 patients (4 after completing only one cycle, while 9 refused further 
treatment after completing the second cycle). Our patients did not experience severe neuropathy. In 
addition, severe events such as sepsis or hematologic toxicity were also uncommon in our study with 
the exception of 1 case of grade 4 thrombocytopenia. 
Oddly, there were more relapses in lumboaortic-inguinal lymph nodes in the chemotherapy arm, 
however, in this study the different distribution of patients with regard to residuum and stage, which 
resulted from a lack of stratification, might have produced a lack of benefit in terms of recurrence and 
survival. 
Currently, tumor cell heterogeneity and clonal selection of resistant tumor cells continue to be 
major obstacles in cancer therapy. In vitro experimental studies are limited in that they cannot represent 
the heterogeneity of cancer cells observed in vivo. On the other hand, some immunohistochemical 
correlation with clinical aspects of disease is starting to emerge [31, 32, 33, 34] and may eventually 
provide clues for further tailoring of therapy to the specific patient. In addition, in programming new 
therapeutic approaches it is necessary to understand the percentage of relapses after complete remission Int. J. Med. Sci. 2004 1(2): 116-125  120 
that are due to residual tumor cells and how many might be due to a perpetuation of carcinogenesis in 
the peritoneal cavity. To date, the most important variable in survival of patients with epithelial ovarian 
cancer is residual disease > 10 cm after first surgery; these patients present with an extremely high 
relapse rate. Thus, “wait and see” is still the main choice for patients who have reached complete 
remission after first-line chemotherapy in the absence of confirmatory data from randomized trials. 
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Tables and Figures 
Table 1. Studies of efficacy of consolidation treatment in ovarian cancer 
 
WAR= whole abdominal radiation; RT = radiotherapy; nihil = no treatment; D.F.= median disease-free survival; 
O.S.= median overall survival; i.p. = intraperitoneal; CCR= complete clinical remission; JM8 = Carboplatin; 
αIFN = interferon α; SL = second look 
Study  Year  N. 
pts.  Stage Treatment 
Residuum 
before 
consolidation 
Efficacy 
Microscopic disease 
(10 pts)  1. Falcone  [35] 
1988 16 IIB-IV  WAR 
< 2 cm (6 pts) 
Slight advantage for 
microscopic disease 
Microscopic disease 
(11 pts)  2. Nicoletto  [36]  1992  18  IIIA-B 
i.p. αIFN x 4 to 
CCR 
+ 4 cycles 
consolidation  < 2 cm (7 pts) 
Possibly effective 
in microscopic 
disease 
i.p. cisplatin x 3   
1989 37  II-IV 
WAR  
i.p. cisplatin might 
be better 
than RT 
3. Menczer  [28,  29] 
1995  21    i.p. cisplatin  CCR 17 SL (10+; 7-) 
i.p. 
cisplatin+etoposide 
does not seem more 
effective than i.p. 
cisplatin alone 
JM8 400 i.p.   
4. Bruzzone  [33]  1997  111   
αIFN+JM8 400 
i.p. 
 
αIFN does not 
improve D.F. or 
O.S. 
Microscopic disease 
(13 pts)  5. Barakat  [37]  1998  36  IIC-IV  i.p. cisplatin 
VP 16 x 3 
Nihil 
i.p. cisplatin 
improved disease-
free survival 
32 pts - WAR   
6. Pickel  [23]  1999  64   
32 pts - nihil   
RT offers promising 
results Int. J. Med. Sci. 2004 1(2): 116-125  123 
Table 2. Patient characteristics 
Characteristics 
Cisplatin 
(n=60 pts) 
Nihil 
(n=61 pts) 
1.  Median Age (years)   55 55 
Range 38-76  16-73 
2. Stage  (FIGO)    
IC  3 (4.9%)  12 (19.7%) 
IIB-C  13 (21.3%)  17 (27.9%) 
IIIA-B-C + IV  45 (73.8%)  32 (52.4%) 
3. Histological  Type    
Serous Papillary  45 (73.8%)  32 (52.5%) 
Undifferentiated  3 (4.9%)  6 (9.8%) 
Clear Cell  2 (3.3%)  2 (3.3%) 
Endometrioid  8 (13.1%)  15 (24.6%) 
Mucinous  −  4 (6.6%) 
Mixed  3 (4.9%)  2 (3.3%) 
4. Histological  Grade    
1-2  30 (49.2%)  34 (55.7%) 
3  31 (50.8%)  27 (44.3%) 
5.  Type of first line chemotherapy    
Anthracyclin-Cyclophosphamide  30 (49.2%)  24 (39.3%) 
Mitoxantrone-Cisplatin  2 (3.3%)  3 (4.9%) 
Cyclophosphamide-Cisplatin  29 (47.5%)  34 (55.7%) 
6.  Type of Surgery    
Laparoscopy  −  1 (1.6%) 
Tumor Reduction  13 (21.3%)  5 (8.2%) 
Radical Surgery  48 (78.7%)  55 (90.2%) 
7.  Postsurgical Residual Disease (first look)    
  Residuum ≤2 cm  51 (83.6%)  55 (90.2%) 
  Residuum >2 cm  10 (16.4%)  6 (9.8%) 
8.  Total number of cycles completed    
0 1  (%)  − 
1 4  (%)  − 
2 9  (%)  − 
3 44  (%)  − 
4 2  (%)  − 
5  −  − 
6 1  (%)  − Int. J. Med. Sci. 2004 1(2): 116-125  124 
Table 3. Toxicity in patients who received Cisplatin consolidation therapy 
Toxicity Grade  1  Grade  2  Grade 3  Grade 4  Total 
1.  Allergic reaction  -  -  1 (1.6%)  -  1 (1.6%) 
2.  Alopecia  -  4 (6.6%)  1 (1.6%)  -  5 (8.2%) 
3.  Hematologic  4 (6.6%)  11 (18.0%)  4 (6.6%)  -  19 (31.1%) 
   - Anemia  2 (3.3%)  -  -  -  2 (3.3%) 
   - Leukopenia  3 (4.9%)  10 (16.4%)  -  -  13 (21.3%) 
   - Neutropenia  2 (3.3%)  -  1 (1.6%)  -  3 (4.9%) 
   - 
Thrombocytopeni
a 
1 (1.6%)  1 (1.6%)  -  1 (1.6%)  3 (4.9%) 
4.  Infection  2 (3.3%)  -  1 (1.6%)  -  3 (4.9%) 
5.  Mucositis  3 (4.9%)  3 (4.9%)  -  1 (1.6%)  7 (11.5%) 
6.  Nausea-Vomiting  1 (1.6%)  10 (16.4%)  17 (27.9%)  10 (16.4%)  38 (62.3%) 
7.  Renal  4  (6.6%)  - - - 4  (6.6%) 
 
Table 4. Relapses: isolated or multiple relapses divided by site. 
Site of relapse 
Cisplatin 
(n=61 pts) 
 
Nihil 
(n=61pts) 
  Total  36 (59.0%)  30 (49.2%) 
1.  Peritoneum  15 (24.6%)  10 (16.4%) 
2.  Retroperitoneum  3 (4.9%)  2 (3.3%) 
3.  Pelvis  5 (8.2%)  11 (18%) 
4.  Lumbo-aortic LN  6 (9.8%)  3 (4.9%) 
5.  Inguinal LN  5 (8.2%)  1 (1.6%) 
6.  Supraclavear LN  2 (3.3%)  1 (1.6%) 
7.  Vaginal dome  1 (1.6%)  5 (8.2%) 
8.  Spleen  1 (1.6%)  2 (3.3%) 
9.  Lung-pleura  5 (8.2%)  6 (9.8%) 
10.  Liver  3 (4.9%)  4 (6.6%) 
11.  CA 125  5 (8.2%)  1 (1.6%) 
12.  Bone  1 (1.6%)  1 (1.6%) 
13.  Rectum-sigma  1 (1.6%)  1 (1.6%) 
14.  Ileo-paraintestinal  1 (1.6%)  3 (4.9%) 
15. 
Peritoneum + Pelvis+ Vaginal 
dome + Rectum-sigma + Ileo-
paraintestinal 
23 (37.7%)  30 (49.2%) 
16. 
Retroperitoneum + Lumbo-
aortic LN + Inguinal LN + 
Supraclavear LN 
16 (26.2%)  7 (11.5%) 
LN = lymph node  Int. J. Med. Sci. 2004 1(2): 116-125  125 
Figure 1: Kaplan-Meier curve of survival from time of randomization. 
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Figure 2: Kaplan-Meier curve of disease-free survival from time of randomization. 
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